Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
Sass MR, Christensen AMB, Christensen ML, Gruber E, Nerdrum H, Pedersen LM, Resch M, Jørgensen TH, Ekstrøm CT, Nielsen J, Vilsbøll T, Fink-Jensen A. Sass MR, et al. Among authors: ekstrom ct. Acta Psychiatr Scand. 2024 Apr 17. doi: 10.1111/acps.13690. Online ahead of print. Acta Psychiatr Scand. 2024. PMID: 38631670
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. Svensson CK, et al. Among authors: ekstrom ct. Acta Psychiatr Scand. 2019 Jan;139(1):26-36. doi: 10.1111/acps.12982. Epub 2018 Nov 28. Acta Psychiatr Scand. 2019. PMID: 30374965 Clinical Trial.
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. Larsen JR, et al. Among authors: ekstrom ct. JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220. JAMA Psychiatry. 2017. PMID: 28601891 Free PMC article. Clinical Trial.
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU, Ekstrøm C, Vinberg M, Nielsen J, Vilsbøll T, Fink-Jensen A. Sass MR, et al. BMJ Open. 2023 Jan 31;13(1):e068652. doi: 10.1136/bmjopen-2022-068652. BMJ Open. 2023. PMID: 36720576 Free PMC article.
High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.
Larsen JR, Svensson CK, Vedtofte L, Jakobsen ML, Jespersen HS, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Holst JJ, Correll CU, Vilsbøll T, Fink-Jensen A. Larsen JR, et al. Among authors: ekstrom ct. CNS Spectr. 2019 Aug;24(4):441-452. doi: 10.1017/S1092852918001311. Epub 2018 Dec 31. CNS Spectr. 2019. PMID: 30596361
SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.
Sass MR, Juul TS, Skov R, Iversen K, Harritshøj LH, Sørensen E, Ostrowski SR, Andersen O, Ekstrøm CT, Ullum H, Nielsen J, Hageman I, Fink-Jensen A. Sass MR, et al. Among authors: ekstrom ct. PLoS One. 2022 Mar 1;17(3):e0264325. doi: 10.1371/journal.pone.0264325. eCollection 2022. PLoS One. 2022. PMID: 35231037 Free PMC article. Clinical Trial.
Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.
Antonsen KK, Klausen MK, Brunchmann AS, le Dous N, Jensen ME, Miskowiak KW, Fisher PM, Thomsen GK, Rindom H, Fahmy TP, Vollstaedt-Klein S, Benveniste H, Volkow ND, Becker U, Ekstrøm C, Knudsen GM, Vilsbøll T, Fink-Jensen A. Antonsen KK, et al. BMJ Open. 2018 Jul 16;8(7):e019562. doi: 10.1136/bmjopen-2017-019562. BMJ Open. 2018. PMID: 30012779 Free PMC article.
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. Among authors: ekstrom ct. JCI Insight. 2022 Oct 10;7(19):e159863. doi: 10.1172/jci.insight.159863. JCI Insight. 2022. PMID: 36066977 Free PMC article. Clinical Trial.
107 results